Article Type
Changed
Fri, 12/09/2022 - 12:52

Key clinical point: Intraoperative cell salvage (ICS) is an effective and safe method for blood loss recovery in patients with a high risk for postpartum hemorrhage (PPH) during cesarean section.

Major finding: Patients who underwent ICS vs received allogeneic red blood cell (RBC) transfusion had significantly higher blood cell count, hemoglobin levels, hematocrit, and fibrinogen levels, and shorter prothrombin time, thrombin time, and activated partial thromboplastin time (all P < .05). ICS treatment did not cause any adverse events.

Study details: This prospective randomized controlled study included 130 patients with a high risk for PPH who underwent elective or emergency cesarean section and were randomly assigned (1:1) to undergo ICS (n = 65) or receive allogeneic RBC transfusion (control; n = 65) if the hemoglobin level was <80 g/L during surgery.

Disclosures: This study was sponsored by the Beijing Science and Technology Commission Research Fund, China. The authors declared no conflicts of interest.

Source: Lei B et al. Intraoperative cell salvage as an effective intervention for postpartum hemorrhage—Evidence from a prospective randomized controlled trial. Front Immunol. 2022;13:953334 (Oct 10). Doi: 10.3389/fimmu.2022.953334

 

Publications
Topics
Sections

Key clinical point: Intraoperative cell salvage (ICS) is an effective and safe method for blood loss recovery in patients with a high risk for postpartum hemorrhage (PPH) during cesarean section.

Major finding: Patients who underwent ICS vs received allogeneic red blood cell (RBC) transfusion had significantly higher blood cell count, hemoglobin levels, hematocrit, and fibrinogen levels, and shorter prothrombin time, thrombin time, and activated partial thromboplastin time (all P < .05). ICS treatment did not cause any adverse events.

Study details: This prospective randomized controlled study included 130 patients with a high risk for PPH who underwent elective or emergency cesarean section and were randomly assigned (1:1) to undergo ICS (n = 65) or receive allogeneic RBC transfusion (control; n = 65) if the hemoglobin level was <80 g/L during surgery.

Disclosures: This study was sponsored by the Beijing Science and Technology Commission Research Fund, China. The authors declared no conflicts of interest.

Source: Lei B et al. Intraoperative cell salvage as an effective intervention for postpartum hemorrhage—Evidence from a prospective randomized controlled trial. Front Immunol. 2022;13:953334 (Oct 10). Doi: 10.3389/fimmu.2022.953334

 

Key clinical point: Intraoperative cell salvage (ICS) is an effective and safe method for blood loss recovery in patients with a high risk for postpartum hemorrhage (PPH) during cesarean section.

Major finding: Patients who underwent ICS vs received allogeneic red blood cell (RBC) transfusion had significantly higher blood cell count, hemoglobin levels, hematocrit, and fibrinogen levels, and shorter prothrombin time, thrombin time, and activated partial thromboplastin time (all P < .05). ICS treatment did not cause any adverse events.

Study details: This prospective randomized controlled study included 130 patients with a high risk for PPH who underwent elective or emergency cesarean section and were randomly assigned (1:1) to undergo ICS (n = 65) or receive allogeneic RBC transfusion (control; n = 65) if the hemoglobin level was <80 g/L during surgery.

Disclosures: This study was sponsored by the Beijing Science and Technology Commission Research Fund, China. The authors declared no conflicts of interest.

Source: Lei B et al. Intraoperative cell salvage as an effective intervention for postpartum hemorrhage—Evidence from a prospective randomized controlled trial. Front Immunol. 2022;13:953334 (Oct 10). Doi: 10.3389/fimmu.2022.953334

 

Publications
Publications
Topics
Article Type
Sections
Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default
Article Series
Clinical Edge Journal Scan: Obstetric Emergencies December 2022
Gate On Date
Tue, 09/27/2022 - 10:00
Un-Gate On Date
Tue, 09/27/2022 - 10:00
Use ProPublica
CFC Schedule Remove Status
Tue, 09/27/2022 - 10:00
Hide sidebar & use full width
render the right sidebar.
Conference Recap Checkbox
Not Conference Recap
Clinical Edge
Display the Slideshow in this Article
Medscape Article
Display survey writer
Reuters content
Disable Inline Native ads
WebMD Article